Findings from the prospective DIRECT (NCT04226937) study demonstrated that an ultrasensitive circulating tumor DNA (ctDNA) assay tracking tumor-specific phased variants (PVs) to detect minimal residual disease (MRD) at the end of first-line…
Phased Variant-MRD ctDNA Assay Outperforms PET in Predicting LBCL Outcomes | Targeted Oncology
